Early withdrawal of ESRD patients Acalabrutinib research buy within 3 years after starting of PD therapy was clearly decreased from 50.9% in our previous study to ∼46% against the total population of withdrawal from PD therapy. Compared with our previous study about the Tokai PD registry, incidence of PD-related peritonitis and withdrawal from PD therapy caused by PD-related peritonitis

were clearly decreased. Conclusion: In the Tokai area of Japan, we recognized that PD-related peritonitis was still one of important complications to prevent long-term PD therapy for ESRD patients. However, having carefully educated PD patients and medical staffs, it might be improved prognosis of PD patients in this study. FERRARI PAOLO1,2, WOODROFFE CLAUDIA1, FILDER SAMANTHA3, D’ORSOGNA LLOYD3 1Department of Nephrology, Fremantle Hospital, Perth, Western Australia, Australia; 2School of Medicine and Pharmacology, University of Western Australia, Australia; 3Department of Immunology, Royal Perth Hospital, Perth, Western RXDX-106 manufacturer Australia Introduction: Kidney paired donation (KPD) is a strategy increasingly used in live donor kidney transplantation to overcome the immunological barriers of HLA or blood group incompatibility, when directed live donor transplantation is not an option because of high level donor-specific antibody (DSA) or anti-blood group antibody

(ABGAb) titre. Methods: A single national KPD program was established in Australia in 2010 and herein we analyse the

number of enrolled pairs, matched recipients, identified chains, and kidney transplants performed within the first 3 years of the program. In the Australian program, virtual crossmatch Epothilone B (EPO906, Patupilone) is used to allocate suitable donors to recipients; matching is based on acceptable mismatches and donors are excluded from matching to recipients with DSAs > 2000 mean fluorescence intensity (MFI). Acceptance of ABO-incompatible donors is allowed in cases where ABGAb titres are deemed amenable to removal by apheresis or immunoabsorption. Results: Thirteen quarterly match runs including 175 pairs and 2 altruistic donors were performed between October 2010 and October 2013. Incompatibility due to DSA accounted for 87% of the listed pairs and 52% were also ABO-incompatible to their co-registered donor. Median calculated panel-reactive antibody (cPRA) in registered recipients was 78% (mean 65 ± 36%). Matches were identified in 125 (71%) patients and 121 of these offers were accepted for crossmatching. A negative crossmatch was reported in 97% of cases; crossmatch positive results were found only in recipients with DSA > 2000MFI. Thirty-four (31%) crossmatch negative patients did not proceed to transplantation after their first match and the major cause of chain breakdown was medical unsuitability of the recipient. Eventually, 80 (65%) patients received a KPD transplant and 34% of these had a cPRA >95%.